Sagetis Biotech, CataloniaBio & HealthTech member, granted an exclusive license to develop, manufacture and commercialise its polymeric coating technology Viroshield™ to French company Aratinga.

This technology is able to modify the behavior of oncolytic viruses, improving their therapeutic effect by different means.

Sagetis Biotech is also developing novel SAG-101, a polymer-coated adenovirus for the treatment of pancreatic ductal adenocarcinoma. It received orphan designation from the European Medicines Agency (EMA) in 2017.

More information

Photo: Eduard Diviu, CEO of Sagetis Biotech